Inactive Instrument

Highlights Response Genetics, Inc. Nasdaq

Equities

US76123U1051

End-of-day quote Nasdaq Other stock markets
- ^USD	-

2016	Response Genetics, Inc Bankruptcy Case Dismissed	CI
2016	Motion for Case Dismissal Filed for Response Genetics, Inc	CI

Highlights

Unlock all the news: Be the first to know and act before the market!

100% Free Registration

Cancer Genetics, Inc. completed the acquisition of substantially all the assets and operations of Response Genetics, Inc.	15-10-08	CI
Cancer Genetics, Inc. entered into an agreement to acquire substantially all the assets and operations from Response Genetics, Inc for $13.8 million.	15-08-09	CI
Response Genetics, Inc. Reports Unaudited Consolidated Earnings Results for the First Quarter Ended March 31, 2015	15-05-14	CI
Response Genetics, Inc. Announces Unaudited Consolidated Financial Results for the Fourth Quarter and Full Year Ended December 31, 2014	15-03-31	CI
Response Genetics, Inc. Secures New York State Department of Health Approval for its ResponseDX(R) Testing Services	14-12-11	CI
Response Genetics, Inc Announces Unaudited Consolidated Earnings Results for the Third Quarter and Nine Months Ended September 30, 2014	14-11-13	CI
Response Genetics, Inc. Launches New and Innovative Non-Small Cell Lung Cancer Profile	14-09-15	CI
Response Genetics, Inc. to Serve as the Molecular Screening Center for ALCHEMIST	14-08-18	CI
Response Genetics, Inc Announces Unaudited Consolidated Earnings Results for the Second Quarter and Six Months Ended June 30, 2014	14-08-14	CI
Response Genetics, Inc Launches New Test for Cancer Immunotherapy Drug Development	14-06-16	CI
Response Genetics, Inc. Announces Commercial Agreement with DxM Diagnostico Molecular	14-05-14	CI
Response Genetics, Inc and Knight Partner for Lung Cancer Sequencing Panel	14-04-28	CI
Response Genetics Enters Next Generation Sequencing Market with Proprietary Panel for Lung Cancer Developed by the Knight Cancer Institute at Oregon Health & Science University	14-04-21	CI
Response Genetics, Inc. to Offer Expanded KRAS Mutation Test to Improve Treatment Decisions for Colorectal Cancer Patients	14-03-10	CI
Response Genetics, Inc. Signs Agreements with Blue Cross Blue Shield	14-01-06	CI
Response Genetics, Inc. Announces Four New Contracts with National PPO Networks	13-11-13	CI
Response Genetics, Inc Announces Payor Contract With Fortified Provider Network	13-10-02	CI
Response Genetics, Inc. Announces Contract with Three Rivers Provider Network	13-09-25	CI
Response Genetics, Inc acquired substantially all of the assets of Pathwork Diagnostics, Inc. from Abingworth LLP and others for $1.2 million.	13-08-22	CI
Response Genetics, Inc. Announces Contract with MultiPlan, Inc	13-08-12	CI

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Highlights Response Genetics, Inc. Nasdaq

Equities

US76123U1051

Highlights

Filters